<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ZANAMIVIR</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>ZANAMIVIR</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Post-exposure prophylaxis of influenza</span>,
            </h4>
            <p class="specificity"><span class="route">By inhalation of powder</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                10 mg once daily for 10 days.</li>
              <li class="dose child"><strong>For children 5&#8211;17 years</strong><br/>
                10 mg once daily for 10 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prevention of influenza during an epidemic</span>,
            </h4>
            <p class="specificity"><span class="route">By inhalation of powder</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                10 mg once daily for up to 28 days.</li>
              <li class="dose child"><strong>For children 5&#8211;17 years</strong><br/>
                10 mg once daily for up to 28 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of influenza</span>,
            </h4>
            <p class="specificity"><span class="route">By inhalation of powder</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                10 mg twice daily for 5 days (for up to 10 days if resistance to oseltamivir suspected).</li>
              <li class="dose child"><strong>For children 5&#8211;17 years</strong><br/>
                10 mg twice daily for 5 days (for up to 10 days if resistance to oseltamivir suspected).</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Reduces replication of influenza A and B viruses by inhibiting viral neuraminidase.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Although safety data are limited, zanamivir can be used in women who are pregnant when the potential benefit outweighs the risk (e.g. during a pandemic).</p>
            </section>
            <section class="generalInformation">
              <p>Use only if potential benefit outweighs risk (e.g. during a pandemic).</p>
            </section>
      </section>




      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Rash,
              </p>
              <p>
                <strong>uncommon:</strong> Angioedema, bronchospasm, dyspnoea, urticaria,
              </p>
              <p>
                <strong>rare:</strong> Neuropsychiatric disorders in children, neuropsychiatric disorders (especially in children and adolescents) in adults, Stevens-Johnson syndrome, toxic epidermal necrolysis,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>Other inhaled drugs should be administered before zanamivir.</p>
            </section>
      </section>


      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA158</h3>
              <p outputclass="specificity">In adults</p> <p outputclass="title">Oseltamivir, zanamivir, and amantadine for prophylaxis of influenza (September 2008)</p> <p>Zanamivir is <b>not</b> a substitute for vaccination, which remains the most effective way of preventing illness from influenza.</p> <ul> <li>Zanamivir is <b>not</b> recommended for seasonal prophylaxis against influenza.</li> <li>When influenza is circulating in the community, zanamivir is an option recommended (in accordance with UK licensing) for post-exposure prophylaxis in at-risk patients who are not effectively protected by influenza vaccine, and who have been in close contact with someone suffering from influenza-like illness in the same household or residential setting. Zanamivir should be given within 36 hours of exposure to influenza. (National surveillance schemes, including those run by Public Health England, should be used to indicate when influenza is circulating in the community).</li> <li>During local outbreaks of influenza-like illness, when there is a high level of certainty that influenza is present, zanamivir may be used for post-exposure prophylaxis in at-risk patients (regardless of influenza vaccination) living in long-term residential or nursing homes.</li> </ul> <p>At risk patients include those aged over 65 years <i>or</i> those who have one or more of the following conditions:</p> <ul> <li>chronic respiratory disease (including asthma and chronic obstructive pulmonary disease);</li> <li>chronic heart disease;</li> <li>chronic renal disease;</li> <li>chronic liver disease;</li> <li>chronic neurological disease;</li> <li>immunosuppression;</li> <li>diabetes mellitus.</li> </ul> <p>The Department of Health in England has advised (November 2010 and April 2011) that &#8216;at risk patients&#8217; also includes patients under 65 years of age who are at risk of developing medical complications from influenza (treatment only) or women who are pregnant.</p> <p>This guidance does not cover the circumstances of a pandemic, an impending pandemic, or a widespread epidemic of a new strain of influenza to which there is little or no immunity in the community.</p><xref format="html" href="http://www.nice.org.uk/TA158">www.nice.org.uk/TA158</xref>
                <a href="http://www.nice.org.uk/TA158" target="_blank">www.nice.org.uk/TA158</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA158</h3>
              <p outputclass="specificity">In children</p> <p outputclass="title">Oseltamivir, zanamivir, and amantadine for prophylaxis of influenza (September 2008)</p> <p>Zanamivir is not a substitute for vaccination, which remains the most effective way of preventing illness from influenza.</p> <ul> <li>Zanamivir is not recommended for seasonal prophylaxis against influenza.</li> <li>When influenza is circulating in the community, zanamivir is an option recommended (in accordance with UK licensing) for post-exposure prophylaxis in at-risk patients who are not effectively protected by influenza vaccine, and who have been in close contact with someone suffering from influenza-like illness in the same household or residential setting. Zanamivir should be given within 36 hours of exposure to influenza. (National surveillance schemes, including those run by Public Health England, should be used to indicate when influenza is circulating in the community.)</li> <li>During local outbreaks of influenza-like illness, when there is a high level of certainty that influenza is present, zanamivir may be used for post-exposure prophylaxis in at-risk patients (regardless of influenza vaccination) living in long-term residential or nursing homes.</li> </ul> <p>At risk patients are those who have one or more of the following conditions:</p> <ul> <li>chronic respiratory disease (including asthma and chronic obstructive pulmonary disease);</li> <li>chronic heart disease;</li> <li>chronic renal disease;</li> <li>chronic liver disease;</li> <li>chronic neurological disease;</li> <li>immunosuppression;</li> <li>diabetes mellitus.</li> </ul> <p>The Department of Health in England has advised (November 2010 and April 2011) that &#8216;at risk patients&#8217; also includes children who are at risk of developing medical complications from influenza (treatment only) or females who are pregnant.</p> <p>This guidance does not cover the circumstances of a pandemic, an impending pandemic, or a widespread epidemic of a new strain of influenza to which there is little or no immunity in the community.</p><xref format="html" href="http://www.nice.org.uk/TA158">www.nice.org.uk/TA158</xref>
                <a href="http://www.nice.org.uk/TA158" target="_blank">www.nice.org.uk/TA158</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA168</h3>
              <p outputclass="specificity">In adults</p> <p outputclass="title">Oseltamivir, zanamivir, and amantadine for treatment of influenza (February 2009)</p> <p>Zanamivir is not a substitute for vaccination, which remains the most effective way of preventing illness from influenza.</p> <ul> <li>When influenza is circulating in the community, zanamivir is an option recommended (in accordance with UK licensing) for the treatment of influenza in at-risk patients who can start treatment within 48 hours (within 36 hours for zanamivir in children) of the onset of symptoms. (National surveillance schemes, including those run by Public Health England, should be used to indicate when influenza is circulating in the community.)</li> <li>During local outbreaks of influenza-like illness, when there is a high level of certainty that influenza is present, zanamivir may be used for treatment in at-risk patients living in long-term residential or nursing homes.</li> </ul> <p>At risk patients include those aged over 65 years <i>or</i> those who have one or more of the following conditions:</p> <ul> <li>chronic respiratory disease (including asthma and chronic obstructive pulmonary disease);</li> <li>chronic heart disease;</li> <li>chronic renal disease;</li> <li>chronic liver disease;</li> <li>chronic neurological disease;</li> <li>immunosuppression;</li> <li>diabetes mellitus.</li> </ul> <p>The Department of Health in England has advised (November 2010 and April 2011) that &#8216;at risk patients&#8217; also includes patients under 65 years of age who are at risk of developing medical complications from influenza (treatment only) or women who are pregnant.</p> <p> This guidance does not cover the circumstances of a pandemic, an impending pandemic, or a widespread epidemic of a new strain of influenza to which there is little or no immunity in the community.</p><xref format="html" href="http://www.nice.org.uk/TA168">www.nice.org.uk/TA168</xref>
                <a href="http://www.nice.org.uk/TA168" target="_blank">www.nice.org.uk/TA168</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA168</h3>
              <p outputclass="specificity">In children</p> <p outputclass="title">Oseltamivir, zanamivir, and amantadine for treatment of influenza (February 2009)</p> <p>Zanamivir is not a substitute for vaccination, which remains the most effective way of preventing illness from influenza.</p> <ul> <li>When influenza is circulating in the community, zanamivir is an option recommended (in accordance with UK licensing) for the treatment of influenza in at-risk patients who can start treatment within 36 hours of the onset of symptoms. (National surveillance schemes, including those run by Public Health England, should be used to indicate when influenza is circulating in the community.)</li> <li>During local outbreaks of influenza-like illness, when there is a high level of certainty that influenza is present, zanamivir may be used for treatment in at-risk patients living in long-term residential or nursing homes.</li> </ul> <p>At risk patients are those who have one or more of the following conditions:</p> <ul> <li>chronic respiratory disease (including asthma and chronic obstructive pulmonary disease);</li> <li>chronic heart disease;</li> <li>chronic renal disease;</li> <li>chronic liver disease;</li> <li>chronic neurological disease;</li> <li>immunosuppression;</li> <li>diabetes mellitus.</li> </ul> <p>The Department of Health in England has advised (November 2010 and April 2011) that &#8216;at risk patients&#8217; also includes children who are at risk of developing medical complications from influenza (treatment only) or females who are pregnant.</p> <p> This guidance does not cover the circumstances of a pandemic, an impending pandemic, or a widespread epidemic of a new strain of influenza to which there is little or no immunity in the community.</p><xref format="html" href="http://www.nice.org.uk/TA168">www.nice.org.uk/TA168</xref>
                <a href="http://www.nice.org.uk/TA168" target="_blank">www.nice.org.uk/TA168</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Asthma
          </li>
          <li>
            chronic pulmonary disease
          </li>
          <li>
            uncontrolled chronic illness
          </li>
        </ul>
        <ul>
          <li>
            <p>Risk of bronchospasm&#8212;short-acting bronchodilator should be available.</p><p>Avoid in severe asthma unless close monitoring possible and appropriate facilities available to treat bronchospasm.</p>
          </li>
        </ul>
      </section>



      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <p>Use of zanamivir for up to 10 days if resistance to oseltamivir suspected is an unlicensed duration.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Except for the treatment and prophylaxis of influenza as indicated in the NICE guidance; endorse prescription &#8216;SLS&#8217;.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of ZANAMIVIR</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76615"><a href="../medicinalForm/PHP76615.html" data-target="#PHP76615" data-action="load">Inhalation powder</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
